MMS Holdings, a data-focused contract research organization (CRO) – announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics, including vaccines, medicines, and medical devices for children.

Biocytogen Pharmaceuticals Co., Ltd. today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines

Theragent, a cell therapy CDMO focused on advancing next-generation cancer and rare disease treatments, has signed a multi-year exclusive contract with Insight68, an AI-driven software provider

NS Pharma, Inc. announced today the first patient enrollment in a Phase 2 clinical study of NS-018 an investigational treatment for myelofibrosis a rare and incurable blood cancer.

National Resilience, Inc., a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a 10-year biomanufacturing partnership with a leading pharmaceutical company for its portfolio of services across Process and Analytical Development, Drug Substance, and Drug Product manufacturing

Renexxion Ireland Limited, a private biopharmaceutical company committed to providing innovative medicines to patients with high unmet need for gastrointestinal disorders, will is pleased to

Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutics.

GreenLab, Inc. announces launch of the biotech startup's proprietary vector technology platform. GreenLab Vector Technology greens recombinant protein manufacturing by transforming novel

As federal authorities widen a multistate investigation into antibiotic-resistant Pseudomonas aeruginosa bacterial contamination linked to EzriCare Artificial Tears eye drops, a woman has now filed a federal lawsuit against EzriCare and retailer Walmart after using the eye drops and suffering

ESSA Pharma Inc. a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that further analyses of initial clinical data